Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adverse events of TDF/lamivudine/dolutegravir vs lamivudine/dolutegravir in virologically suppressed adolescents with HIV
TCTR20240630004Phase 4Unknown
- Sponsor
- Faculty of Medicine, Chulalongkorn University
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of dolutegravir, lamivudine, tenofovir disoproxil fumarate in human immunodeficiency virus infection (HIV), sponsored by Faculty of Medicine, Chulalongkorn University. Status: unknown.
02
Drugs
dolutegravirlamivudinetenofovir disoproxil fumarate
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on TCTR20240630004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20240630004.